275 related articles for article (PubMed ID: 12395703)
1. [German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
Dominiak P; Zidek W
MMW Fortschr Med; 2002 Sep; 144(38):47. PubMed ID: 12395703
[No Abstract] [Full Text] [Related]
2. [What are the consequences of the LIFE Study for general practice].
Zidek W
MMW Fortschr Med; 2002 Sep; 144(38):48. PubMed ID: 12395704
[No Abstract] [Full Text] [Related]
3. [Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
MMW Fortschr Med; 2002 Sep; 144(38):14. PubMed ID: 12395694
[No Abstract] [Full Text] [Related]
4. [Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
MMW Fortschr Med; 2002 May; 144(20):60-1. PubMed ID: 12119887
[No Abstract] [Full Text] [Related]
5. [Results from the LIFE study: promising effects of new hypertensive agents].
Nilsson P; Kahan T
Lakartidningen; 2002 Apr; 99(16):1792-4. PubMed ID: 12043477
[No Abstract] [Full Text] [Related]
6. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
[No Abstract] [Full Text] [Related]
7. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
[TBL] [Abstract][Full Text] [Related]
9. [Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
Einecke D
MMW Fortschr Med; 2002 Apr; 144(14):4-5. PubMed ID: 12014276
[No Abstract] [Full Text] [Related]
10. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
11. [LIFE study proves preventive action. With losartan to do even more against stroke].
Baumgart P
MMW Fortschr Med; 2003; 145 Suppl 1():7-8. PubMed ID: 12958796
[No Abstract] [Full Text] [Related]
12. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Fossum E; Moan A; Kjeldsen SE; Devereux RB; Julius S; Snapinn SM; Edelman JM; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Dahlöf B;
J Am Coll Cardiol; 2005 Sep; 46(5):770-5. PubMed ID: 16139123
[TBL] [Abstract][Full Text] [Related]
13. [Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
Schmieder RE; Schneider MP
MMW Fortschr Med; 2002 Oct; 144(42):45-6. PubMed ID: 12533997
[No Abstract] [Full Text] [Related]
14. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
MMW Fortschr Med; 2003 May; 145(19):53. PubMed ID: 12813983
[No Abstract] [Full Text] [Related]
16. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cardiovascular morbidity with angiotension receptor blockade: life after LIFE.
Diabet Med; 2002 Sep; 19 Suppl 5():6. PubMed ID: 12207800
[No Abstract] [Full Text] [Related]
19. Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
Bourassa MG
J Am Coll Cardiol; 2005 Mar; 45(5):720-1. PubMed ID: 15734616
[No Abstract] [Full Text] [Related]
20. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
